BMP2 was described to sensitize resistant GBM cells to TMZ-induced cell death; and co-treatment with BMP2 and TMZ was described to induce differentiation, downregulation of HIF1α activity, and consequently diminishing the expression of MGMT [105], which mediates TMZ resistance. Here, MGMT is linked to glioblastoma.